References
Robinson WH, Genovese MC, Moreland LW. Demyelinating and neurologic events reported in association with tumor necrosis factor a antagonism: by what mechanisms could tumor necrosis factor α antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis? Arthritis Rheum 2001; 44: 1977–83.
Cope AP, Liblau RS, Yang XD, et al. Chronic tumor necrosis factor alters T cell responses by attenuating T cell receptor signaling. J Exp Med 1997; 185: 1573–84.
Cope A, Ettinger R, McDevitt H. The role of TNF α and related cytokines in the development and function of the autoreactive T-cell repertoire. Res Immunol 1997; 148: 307–12.
Stübgen JP. Tumor necrosis factor-α antagonists and neuropathy. Muscle Nerve 2008; 37: 281–92.
Lozeron P, Denier C, Lacroix C, Adams D. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-α- blocker therapy. Arch Neurol 2009; 66: 490–7.
Dalakas MC, Medscape MC. Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 2011; 7: 507–17.
Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann Neurol 2000; 47: 765–75.
Dalakas MC, Engel WK. Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 1980; 37: 637–40.
Bachmann R, Eugster HP, Frei K, Fontana A, Lassmann H. Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol 1999; 154: 1417–22.
Mahil SK, Andrews TC, Brierley C, Barker JN, Smith CH. Demyelination during tumour necrosis factor antagonist therapy for psoriasis: a case report and review of the literature. J Dermatolog Treat 2013; 24: 38–49.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Nakao, M., Asano, Y., Nakamura, K. et al. The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris. Eur J Dermatol 26, 404–405 (2016). https://doi.org/10.1684/ejd.2016.2781
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2016.2781